Drugs in Dev.
Hematology
Phase I/ Phase II
China 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CM313
Therapeutic Area : Hematology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia
Details : CM313 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Anemia, Aplastic.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
January 24, 2025
Lead Product(s) : CM313
Therapeutic Area : Hematology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TNP-2092
Therapeutic Area : Hematology
Study Phase : Phase I/ Phase II
Sponsor : The First Hospital of Jilin University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TNP-2092 is a Antibiotic drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hyperammonemia.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 18, 2023
Lead Product(s) : TNP-2092
Therapeutic Area : Hematology
Highest Development Status : Phase I/ Phase II
Sponsor : The First Hospital of Jilin University
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CM355
Therapeutic Area : Hematology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CM355 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hematoma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
January 27, 2022
Lead Product(s) : CM355
Therapeutic Area : Hematology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Hetrombopag Olamine
Therapeutic Area : Hematology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hetrombopag Olamine is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Anemia, Aplastic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 14, 2018
Lead Product(s) : Hetrombopag Olamine
Therapeutic Area : Hematology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
